Kymera Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results significantly beat consensus on the top and bottom lines, driven by a massive $65.0M in collaboration revenue—nearly double the $32.8M expected—primarily from milestone payments by Gilead and Sanofi. Net loss was narrower than anticipated at $61.2M vs. $71.0M expected, resulting in a GAAP EPS of -$0.62, outperforming the -$0.74 consensus. Additionally, the company accelerated its KT-621 Phase 2b data readout to year-end 2026 and extended its cash runway into 2029 with $1.5B in liquidity.